ClinicalTrials.gg
CompletedNCT04886518Updated Sep 4, 2026Results posted

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

A Phase 2 interventional study of Pitolisant Oral Tablet and Placebo oral tablet in Myotonic Dystrophy 1 and Excessive Daytime Sleepiness, sponsored by Harmony Biosciences Management, Inc.. Completed at 13 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Enrollment
18th of 22
30 · median 46
Started
2021
with 3 others
Phase 2
5 of 43
1 open now
Registered
16th of 43
by date

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 18th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 2, and was the 16th registered.

Myotonic Dystrophy

126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Myotonic Dystrophy Type 1 ages 18 to 65 years.

The secondary objectives of this study are to assess the impact of pitolisant on fatigue, cognitive function and the burden of disease along with assessing the long-term safety and effectiveness of pitolisant in patients with Myotonic Dystrophy Type 1 ages 18 to 65 years.

Read the detailed description

The study will consist of a Screening Period, an 11-week Double-Blind Treatment Phase (including a 3-week Titration Period and an 8-week Stable Dose Period), and an optional Open Label Extension (OLE) Phase. The OLE Phase will last approximately one year for each patient or until the Sponsor elects to terminate the study.

Approximately 30 patients ages 18 to 65 years who meet all eligibility criteria will be randomized at the Baseline Visit in a 1:1:1 ratio to lower dose pitolisant, higher dose pitolisant, or matching placebo. In the Double-Blind Treatment Phase, patients will be titrated to their randomized stable dose of study drug during the 3-week Titration Period.

After completion of the 3-week Titration Period, patients will continue to take study drug at their randomized stable dose once daily in the morning upon wakening for an additional 8 weeks of blinded treatment (Stable Dose Period). The duration of the Double-Blind Treatment Phase will be 11 weeks.

Following the 11-week Double-Blind Treatment Phase, eligible patients will be given the opportunity to participate in an optional OLE Phase. During the OLE Phase, all eligible patients will receive treatment with open-label pitolisant. Patients will first undergo a 3-week Titration Period to a maximum target dose, after which they will continue to take their dose of pitolisant once daily in the morning upon wakening until the end of the study. The patient's dose of pitolisant may be adjusted during the OLE phase.

03

Conditions studied

  • Myotonic Dystrophy 1
  • Excessive Daytime Sleepiness
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is able to provide voluntary, written .
  2. Has a diagnosis of DM1 confirmed by genetic testing (cytosine-thymine-guanine [CTG] repeat of ≥100) from the Screening Visit.
  3. Male or female patients ages 18 to 65 years at the time of enrollment.
  4. Has a Clinical Global Impression of Severity (CGI-S) assessment of moderate or severe for overall severity of EDS at Screening.
  5. If on a wake-promoting treatment that could affect EDS (including stimulants, modafinil, and armodafinil):

    1. Must be on a stable dose for at least 2 months prior to Screening and agree to continue the stable dose for the duration of the Double-Blind Treatment Phase of the study (dose adjustments will be permitted in the OLE Phase).
    2. If not on a stable dose for 2 months prior to Screening, for 5 half-lives prior to randomization and agree to remain off these treatments for the duration of the Double-Blind Treatment Phase of the study.
  6. Washout of cannabidiol and tetrahydrocannabinol for 28 days prior to randomization and agree to remain off for the duration of the Double-Blind Treatment Phase of the study.
  7. Able to walk independently with or without an assistive device (e.g., cane, walker, orthoses allowed).
  8. A patient who is a female of (FCBP) must have a negative serum pregnancy test at the Screening Visit and negative urine pregnancy test at the Baseline Visit and agree to remain abstinent or use an effective method of non-hormonal to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug.
  9. In the opinion of the Investigator, the patient is capable of understanding and complying with the protocol and administration of oral study drug.

Exclusion criteria

Exclusion Criteria:

  1. Has a diagnosis of another genetic or chromosomal disorder that is distinct from DM1 and that is not being managed adequately in the opinion of the Investigator.
  2. Experiences \<6 hours on average of sleep per night based on their sleep diary during Screening (patients need to record at least 7 of 10 consecutive nights including 2 nights that fall on a weekend in their sleep diary during Screening).
  3. Consistently consumes >600 mg of caffeine per day and is unable/unwilling to reduce caffeine intake to \<600 mg per day for the duration of the Double-Blind Treatment Phase of the study; caffeine intake should remain consistent during Screening and throughout the Double-Blind Treatment Phase of the study.
  4. Does not agree to discontinue any prohibited medication or substances listed in the protocol.
  5. Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study (Double-Blind Treatment Phase and OLE Phase) and for 21 days after final dose of study drug.
  6. Participation in an interventional research study involving another medication or device in the 28 days prior to enrollment; patients who undergo a of an investigational medication of at least 5 half-lives can be enrolled in the Double-Blind Treatment Phase of the study. Patients considering participation in another interventional research study in the OLE Phase must consult with the Investigator who will consult with the Medical Monitor.
  7. Has a primary diagnosis of severe psychiatric illness.
  8. Patients taking antidepressants who have not been on a stable dose of their antidepressant for at least 12 weeks prior to Screening; for patients on a stable dose of their antidepressant for at least 12 weeks prior to Screening, must agree to continue their stable dose for the duration of the Double-Blind Treatment Phase of the study. Dose adjustments will be permitted in the OLE Phase. In the Double-Blind Treatment Phase of the study, antidepressants that are strong CYP2D6 inhibitors are exclusionary.
  9. Has a history of sleep-disordered breathing or another underlying sleep disorder that in the opinion of the Investigator is a main contributory factor to the patient's EDS.
  10. Has a diagnosis of end-stage renal disease (ESRD; estimated [eGFR] of \<15 mL/minute/1.73 m2) or severe hepatic impairment ( C).
  11. Has a diagnosis of moderate or severe renal impairment (eGFR ≥15 to ≤59 mL/minute/1.73 m2) or moderate hepatic impairment (Child-Pugh B) at Screening or during the Double-Blind Treatment Phase.
  12. Has a family history of sudden cardiac death, unexplained death, or death from a primary dysrhythmia potentially associated with in any family member (i.e., first degree relative such as parent, sibling, or offspring).
  13. Has a history of unexplained syncope.
  14. Has a history of long corrected QT interval (QTc) syndrome or corrected QT interval using Fridericia's formula (QTcF) >450 msec for males or >470 msec for females (QTcF = QT / 3√ RR) sustained atrial fibrillation (AF) or \<50%.
  15. Has a history of documented symptomatic arrhythmias (e.g., , Holter monitor).
  16. Electrocardiogram abnormalities during a 10-second, 12-lead ECG at Screening of first degree atrioventricular block (AVB; PR interval >220 msec), QRS >120 msec, heart rate (HR) \<50 beats per minute (bpm), marked T-wave abnormalities, more than single atrial premature complexes (APCs) or premature ventricular contractions (PVCs), left bundle branch block, or Brugada pattern type 1.

    Note: Patients with 1st degree AVB with a PR interval >220 msec, who are treated prophylactically with an allowable implanted device are not excluded from the study.

  17. Based on Holter monitor, any episode of 3rd degree AVB, any prolonged episode of second degree AVB (>2 episodes during waking hours, >6 episodes during sleep), any prolonged episode of 2nd degree AVB (>10 seconds), any asystole longer than 3.5 seconds, any run of ventricular tachycardia (VT) >6 beats, frequent runs of non-sustained VT (>5/24 hour), >400 PVCs/24 hours, AF or paroxysmal AF, or frequent or complex atrial arrhythmias.
  18. Has history of (NYHA) class III or class IV heart failure.
  19. Has an implanted defibrillator or implanted biventricular pacemaker. Note: Patients with implanted univentricular pacemakers that are used prophylactically to prevent or treat bradycardia or heart block may be included.
  20. Is receiving a medication known to prolong the QT interval.
  21. Has a history of hypokalemia or hypomagnesemia that cannot be adequately controlled by supplementation.
  22. Has serum potassium or magnesium levels that are outside of the normal reference ranges and considered clinically significant at Screening. Patients with mild hyperkalemia that, in the opinion of the Investigator, does not pose an arrhythmia threat may be included.
  23. Is receiving a concomitant medication that is known to be a strong cytochrome P450 (CYP) 2D6 inhibitor, a strong inducer; or a centrally acting histamine 1 receptor (H1R) antagonist (sedating antihistamine).

    Note: Patients who undergo a washout of these medications of at least 5 half-lives may be enrolled in the Double-Blind Treatment Phase of the study.

    Note: Use of strong CYP2D6 inhibitors and strong CYP3A4 inducers is allowed during the OLE Phase; however, adjustment of pitolisant dose is required. Although not prohibited during the OLE Phase of the study, use of centrally acting or sedating H1R antagonists should be avoided.

  24. Is a known CYP2D6 poor metabolizer (PM).
  25. Regular use (more than twice per week) of any sleep-promoting treatments that could affect EDS and not willing to limit use to no more than twice per week during Screening and for the duration of the Double-Blind Treatment Phase of the study (use of sleep-promoting agents are not allowed within one day prior to study-related assessments).
  26. Has abnormal laboratory values at Screening that are clinically significant as determined by the Investigator.
  27. Has initiated any new or change in allied health therapies or interventions that can interfere with the study outcomes within 28 days prior to randomization and that are prohibited during the Double-Blind Treatment Phase of the study, based on the Investigator's judgment.
  28. Has a current or recent (within 1 year) history of a substance use disorder or dependence disorder, including alcohol and caffeine use disorders as defined in the , 5th Edition (DSM-V).
  29. Has planned surgery during the Double-Blind Treatment Phase of the study; planned surgery is permitted during the OLE Phase.
  30. Has a significant risk of committing suicide or suicidality based on history, routine psychiatric examination, Investigator's judgment, or who has an answer of "yes" on any question other than questions 1 to 3 on the Columbia-Suicide Severity Rating Scale.
  31. Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to an unstable or uncontrolled medical condition or one that might interfere with the conduct of the study, confound interpretation of study results, pose a health risk to the patient, or compromise the integrity of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Higher dose pitolisant

    Double-Blind Treatment Phase: Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning.

    Drug: Pitolisant Oral Tablet

  • Active comparator
    Lower dose pitolisant

    Double-Blind Treatment Phase: Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning

    Drug: Pitolisant Oral Tablet

  • Placebo comparator
    Placebo

    Double-Blind Treatment Phase: Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets

    Drug: Placebo oral tablet

Interventions

  • Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant. Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.

  • DrugPlacebo oral tablet

    Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.

06

What researchers measure

Primary outcomes

  1. Change in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score

    The score of the DSS ranges from 0 to 15. A decrease in the DSS score represents an improvement in EDS.

    Time frame: Baseline to Week 11

Secondary outcomes

  1. Change in Fatigue Based on Change in Fatigue Severity Scale (FSS) Score

    The score of the FSS ranges from 0 to 63. A decrease in the FSS score represents an improvement in fatigue.

    Time frame: Baseline to Week 11

  2. Change in Psychomotor Function Based on Change in Cogstate Detection Test

    The Cogstate Detection Test is a computerized test. A faster speed represents an improvement in psychomotor test performance.

    Time frame: Baseline to Week 11

  3. Change in Attention Based on Change in Cogstate Identification Test

    The Cogstate Identification Test is a computerized test. A faster speed represents an improvement in attention test performance.

    Time frame: Baseline to Week 11

  4. Change in Working Memory Based on Change in Cogstate One Back Test

    The Cogstate One Back Test is a computerized test. A faster speed represents a better working memory test performance.

    Time frame: Baseline to Week 11

  5. Change in Burden of Disease Based on Change in Myotonic Dystrophy Health Index (MDHI)

    The MDHI score ranges from 0 to 100. A decrease in the MDHI score represents an improvement in overall burden of disease.

    Time frame: Baseline to Week 11

  6. Change in Excessive Daytime Sleepiness (EDS) Based on Change in Epworth Sleepiness Scale (ESS) Score

    The score of the ESS ranges from 0 to 24. A decrease in the ESS score represents an improvement in EDS.

    Time frame: Baseline to Week 11

  7. Change in Excessive Daytime Sleepiness (EDS) Based on Change in Clinical Global Impression of Severity (CGI-S)

    The CGI-S is a one-item scale that ranges from 0 to 4 with 0 being no EDS and 4 being severe EDS. The scale is completed by the site investigator/clinician. The higher the CGI-S score, the more severe the clinician's perception of the patient's symptoms of EDS.

    Time frame: Baseline to Week 11

  8. Change in Excessive Daytime Sleepiness (EDS) Based on Change in Patient Global Impression of Severity (PGI-S)

    PGI-S is a one-item scale that ranges from 0 to 4 with 0 being no EDS and 4 being severe EDS. The scale is completed by the patient. The higher the PGI-S score, the more severe the patient's perception of excessive daytime sleepiness.

    Time frame: Baseline to Week 11

  9. Change in Sustained Attention Based on Sustained Attention to Response Task (SART)

    The Sustained Attention to Response Test provides a measure of vigilance and sustained attention. A number ranging from 1 to 9 is presented on screen. The subject must press a predetermined button (the YES external button) as soon as the number is presented, except when the number is a 3. The number 3 is the default number (no-go stimulus) for which a response should be inhibited, and the subject should not press the predetermined button. The no-go stimulus can be configured to be a number other than 3. Performance is measured by calculating the number of errors made during the test over the course of 225 trials. Performance is measured by calculating the error score, which is the sum of trials where a response was provided when a 3 was presented and trials where no response was provided when a number other than 3 was presented. A decrease in the SART score represents an improvement in sustained attention.

    Time frame: Baseline to Week 11

07

Results

Posted Apr 25, 2025

Participant flow

Double-Blind Treatment Phase (DBTP)
Participant flow — Double-Blind Treatment Phase (DBTP)
MilestoneHigher Dose Pitolisant (DBTP)Lower Dose Pitolisant (DBTP)Placebo (DBTP)Pitolisant (OLE)
Started1010100
Completed89100
Not completed2100
Withdrew: Other: not specified1000
Withdrew: Adverse event0100
Withdrew: Withdrawal by subject1000
Open-label Extension (OLE) Phase
Participant flow — Open-label Extension (OLE) Phase
MilestoneHigher Dose Pitolisant (DBTP)Lower Dose Pitolisant (DBTP)Placebo (DBTP)Pitolisant (OLE)
Started00024
Completed00015
Not completed0009
Withdrew: Adverse event0002
Withdrew: Withdrawal by subject0006
Withdrew: Other: not specified0001

Outcome measures

PrimaryChange in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score

The score of the DSS ranges from 0 to 15. A decrease in the DSS score represents an improvement in EDS.

Time frame:
Baseline to Week 11
Reported as:
Mean · score on a scale
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score
score on a scaleHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score-3.8 ± 1.98-1.8 ± 1.910.0 ± 2.29
SecondaryChange in Fatigue Based on Change in Fatigue Severity Scale (FSS) Score

The score of the FSS ranges from 0 to 63. A decrease in the FSS score represents an improvement in fatigue.

Time frame:
Baseline to Week 11
Reported as:
Mean · score on a scale
Change in Fatigue Based on Change in Fatigue Severity Scale (FSS) Score
score on a scaleHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Fatigue Based on Change in Fatigue Severity Scale (FSS) Score-0.86 ± 1.487-0.36 ± 0.367-0.13 ± 0.529
SecondaryChange in Psychomotor Function Based on Change in Cogstate Detection Test

The Cogstate Detection Test is a computerized test. A faster speed represents an improvement in psychomotor test performance.

Time frame:
Baseline to Week 11
Reported as:
Mean · log10 ms
Change in Psychomotor Function Based on Change in Cogstate Detection Test
log10 msHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Psychomotor Function Based on Change in Cogstate Detection Test0.02 ± 0.058-0.05 ± 0.0610.01 ± 0.037
SecondaryChange in Attention Based on Change in Cogstate Identification Test

The Cogstate Identification Test is a computerized test. A faster speed represents an improvement in attention test performance.

Time frame:
Baseline to Week 11
Reported as:
Mean · log10 ms
Change in Attention Based on Change in Cogstate Identification Test
log10 msHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Attention Based on Change in Cogstate Identification Test0.00 ± 0.035-0.02 ± 0.076-0.02 ± 0.052
SecondaryChange in Working Memory Based on Change in Cogstate One Back Test

The Cogstate One Back Test is a computerized test. A faster speed represents a better working memory test performance.

Time frame:
Baseline to Week 11
Reported as:
Mean · log10 ms
Change in Working Memory Based on Change in Cogstate One Back Test
log10 msHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Working Memory Based on Change in Cogstate One Back Test0.00 ± 0.062-0.01 ± 0.0320.00 ± 0.050
SecondaryChange in Burden of Disease Based on Change in Myotonic Dystrophy Health Index (MDHI)

The MDHI score ranges from 0 to 100. A decrease in the MDHI score represents an improvement in overall burden of disease.

Time frame:
Baseline to Week 11
Reported as:
Mean · score on a scale
Change in Burden of Disease Based on Change in Myotonic Dystrophy Health Index (MDHI)
score on a scaleHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Burden of Disease Based on Change in Myotonic Dystrophy Health Index (MDHI)-9.14 ± 13.277-2.89 ± 8.5100.42 ± 5.529
SecondaryChange in Excessive Daytime Sleepiness (EDS) Based on Change in Epworth Sleepiness Scale (ESS) Score

The score of the ESS ranges from 0 to 24. A decrease in the ESS score represents an improvement in EDS.

Time frame:
Baseline to Week 11
Reported as:
Mean · score on a scale
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Epworth Sleepiness Scale (ESS) Score
score on a scaleHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Epworth Sleepiness Scale (ESS) Score-4.9 ± 3.981.3 ± 2.83-0.1 ± 2.51
SecondaryChange in Excessive Daytime Sleepiness (EDS) Based on Change in Clinical Global Impression of Severity (CGI-S)

The CGI-S is a one-item scale that ranges from 0 to 4 with 0 being no EDS and 4 being severe EDS. The scale is completed by the site investigator/clinician. The higher the CGI-S score, the more severe the clinician's perception of the patient's symptoms of EDS.

Time frame:
Baseline to Week 11
Reported as:
Mean · score on a scale
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Clinical Global Impression of Severity (CGI-S)
score on a scaleHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Clinical Global Impression of Severity (CGI-S)-0.9 ± 0.64-0.2 ± 0.44-0.1 ± 0.32
SecondaryChange in Excessive Daytime Sleepiness (EDS) Based on Change in Patient Global Impression of Severity (PGI-S)

PGI-S is a one-item scale that ranges from 0 to 4 with 0 being no EDS and 4 being severe EDS. The scale is completed by the patient. The higher the PGI-S score, the more severe the patient's perception of excessive daytime sleepiness.

Time frame:
Baseline to Week 11
Reported as:
Mean · score on a scale
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Patient Global Impression of Severity (PGI-S)
score on a scaleHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Patient Global Impression of Severity (PGI-S)-0.5 ± 0.760.0 ± 1.0-0.4 ± 0.84
SecondaryChange in Sustained Attention Based on Sustained Attention to Response Task (SART)

The Sustained Attention to Response Test provides a measure of vigilance and sustained attention. A number ranging from 1 to 9 is presented on screen. The subject must press a predetermined button (the YES external button) as soon as the number is presented, except when the number is a 3. The number 3 is the default number (no-go stimulus) for which a response should be inhibited, and the subject should not press the predetermined button. The no-go stimulus can be configured to be a number other than 3. Performance is measured by calculating the number of errors made during the test over the course of 225 trials. Performance is measured by calculating the error score, which is the sum of trials where a response was provided when a 3 was presented and trials where no response was provided when a number other than 3 was presented. A decrease in the SART score represents an improvement in sustained attention.

Time frame:
Baseline to Week 11
Reported as:
Mean · scores on a scale
Change in Sustained Attention Based on Sustained Attention to Response Task (SART)
scores on a scaleHigher Dose PitolisantLower Dose PitolisantPlacebo
Change in Sustained Attention Based on Sustained Attention to Response Task (SART)-2.33 ± 5.4281.43 ± 4.46721.88 ± 68.689

Adverse events

Collected over DBTP: First dose of study drug in DBTP up to 11 weeks; OLE Phase: First dose of study drug in OLE phase up to 62 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Higher Dose Pitolisant (DBTP)0/10 (0%)0/10 (0%)8/10 (80%)
Lower Dose Pitolisant (DBTP)0/10 (0%)0/10 (0%)7/10 (70%)
Placebo (DBTP)0/10 (0%)0/10 (0%)8/10 (80%)
Pitolisant (OLE)0/24 (0%)2/24 (8.3%)16/24 (66.7%)
Most frequent serious events
Most frequent serious events
EventHigher Dose Pitolisant (DBTP)Lower Dose Pitolisant (DBTP)Placebo (DBTP)Pitolisant (OLE)
Foot fractureInjury, poisoning and procedural complications0/100/100/101/24
Precursor T-lymphoblastic lymphoma/leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/100/101/24
Most frequent other events
Showing 10 of 79
Most frequent other events
EventHigher Dose Pitolisant (DBTP)Lower Dose Pitolisant (DBTP)Placebo (DBTP)Pitolisant (OLE)
HeadacheNervous system disorders5/101/103/103/24
InsomniaPsychiatric disorders1/104/103/106/24
NauseaGastrointestinal disorders3/101/101/101/24
COVID-19Infections and infestations0/102/102/103/24
Decreased appetiteMetabolism and nutrition disorders2/101/100/101/24
MigraineNervous system disorders2/100/100/101/24
AnxietyPsychiatric disorders0/102/100/102/24
ConstipationGastrointestinal disorders0/100/100/103/24
Gastroenteritis viralInfections and infestations0/100/100/103/24
NasopharyngitisInfections and infestations0/100/100/103/24

Baseline characteristics

Baseline characteristics are provided for the double-blind safety population which included all participants who are enrolled and took at least one dose of double-blind study drug.

Age, Categorical
Age, Categorical(Participants)Higher Dose PitolisantLower Dose PitolisantPlaceboTotal
<=18 years0000
Between 18 and 65 years10101030
>=65 years0000
Age, Continuous
Age, Continuous(years)Higher Dose PitolisantLower Dose PitolisantPlaceboTotal
Median36.5 (20 to 55)42.0 (28 to 50)41.0 (27 to 60)40.0 (20 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)Higher Dose PitolisantLower Dose PitolisantPlaceboTotal
Female44513
Male66517
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Higher Dose PitolisantLower Dose PitolisantPlaceboTotal
Hispanic or Latino1001
Not Hispanic or Latino9101029
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Higher Dose PitolisantLower Dose PitolisantPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White9101029
More than one race1001
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Higher Dose PitolisantLower Dose PitolisantPlaceboTotal
Canada45312
United States65718
Daytime Sleepiness Scale (DSS)
Daytime Sleepiness Scale (DSS)(units on a scale)Higher Dose PitolisantLower Dose PitolisantPlaceboTotal
Mean8.5 ± 3.217.3 ± 1.167.9 ± 3.227.8 ± 2.74
08

Study locations

13 sites
  • UCI Center for Clinical Research
    Irvine, California 92697, United States
  • University of Colorado School of Medicine
    Aurora, Colorado 80045, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Rare Disease Research
    Atlanta, Georgia 30329, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Kennedy Krieger Institute Center for Genetic Muscle Disorders
    Baltimore, Maryland 21205, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest
    Winston-Salem, North Carolina 27157, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • The Ottawa Hospital
    Ottawa, Ontario, Canada
  • Hôpital de Chicoutimi
    Chicoutimi, Quebec, Canada
09

References and documents

Publications

  • D'Ambrosio ES, Chuang K, David WS, Amato AA, Gonzalez-Perez P. Frequency and type of cancers in myotonic dystrophy: A retrospective cross-sectional study. Muscle Nerve. 2023 Aug;68(2):142-148. doi: 10.1002/mus.27801. Epub 2023 Mar 27. PubMed 36790141 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Oct 2023, 27 months.

Results were first posted in Apr 2025, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 14, 2021
StartActual
Jun 28, 2021
Primary completionActual
Oct 6, 2023
CompletionActual
Oct 31, 2024
Results first posted
Apr 25, 2025
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04886518
Responsible party
Sponsor
First posted
May 14, 2021
Start date
Jun 28, 2021
Primary completion
Oct 6, 2023
Completion
Oct 31, 2024
Results posted
Apr 25, 2025
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitolisant

Start the discussion